JP2017523184A5 - - Google Patents

Download PDF

Info

Publication number
JP2017523184A5
JP2017523184A5 JP2017504404A JP2017504404A JP2017523184A5 JP 2017523184 A5 JP2017523184 A5 JP 2017523184A5 JP 2017504404 A JP2017504404 A JP 2017504404A JP 2017504404 A JP2017504404 A JP 2017504404A JP 2017523184 A5 JP2017523184 A5 JP 2017523184A5
Authority
JP
Japan
Prior art keywords
seq
composition
polypeptide
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017504404A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017523184A (ja
JP6940916B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/042684 external-priority patent/WO2016019034A1/en
Publication of JP2017523184A publication Critical patent/JP2017523184A/ja
Publication of JP2017523184A5 publication Critical patent/JP2017523184A5/ja
Priority to JP2021142801A priority Critical patent/JP2021191781A/ja
Application granted granted Critical
Publication of JP6940916B2 publication Critical patent/JP6940916B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017504404A 2014-07-30 2015-07-29 フラジェリン組成物および使用 Expired - Fee Related JP6940916B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021142801A JP2021191781A (ja) 2014-07-30 2021-09-01 フラジェリン組成物および使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462031116P 2014-07-30 2014-07-30
US62/031,116 2014-07-30
US201562110744P 2015-02-02 2015-02-02
US62/110,744 2015-02-02
US201562117366P 2015-02-17 2015-02-17
US62/117,366 2015-02-17
PCT/US2015/042684 WO2016019034A1 (en) 2014-07-30 2015-07-29 Flagellin compositons and uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021142801A Division JP2021191781A (ja) 2014-07-30 2021-09-01 フラジェリン組成物および使用

Publications (3)

Publication Number Publication Date
JP2017523184A JP2017523184A (ja) 2017-08-17
JP2017523184A5 true JP2017523184A5 (enExample) 2021-01-07
JP6940916B2 JP6940916B2 (ja) 2021-09-29

Family

ID=55218277

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017504404A Expired - Fee Related JP6940916B2 (ja) 2014-07-30 2015-07-29 フラジェリン組成物および使用
JP2017504354A Expired - Fee Related JP6646039B2 (ja) 2014-07-30 2015-07-30 フラジェリンベースの薬剤および効果的なワクチン接種を含めた使用
JP2021142801A Pending JP2021191781A (ja) 2014-07-30 2021-09-01 フラジェリン組成物および使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017504354A Expired - Fee Related JP6646039B2 (ja) 2014-07-30 2015-07-30 フラジェリンベースの薬剤および効果的なワクチン接種を含めた使用
JP2021142801A Pending JP2021191781A (ja) 2014-07-30 2021-09-01 フラジェリン組成物および使用

Country Status (14)

Country Link
US (9) US10202426B2 (enExample)
EP (2) EP3174893B1 (enExample)
JP (3) JP6940916B2 (enExample)
KR (1) KR20170031251A (enExample)
CN (2) CN107087411B (enExample)
AU (2) AU2015296555B2 (enExample)
BR (1) BR112017001796A2 (enExample)
CA (2) CA2994218A1 (enExample)
EA (2) EA035372B1 (enExample)
ES (1) ES2816630T3 (enExample)
IL (2) IL250331B (enExample)
MX (2) MX385845B (enExample)
WO (2) WO2016019034A1 (enExample)
ZA (1) ZA201701286B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6940916B2 (ja) * 2014-07-30 2021-09-29 ゲノム プロテクション，インコーポレイテッド フラジェリン組成物および使用
WO2016079899A1 (ja) 2014-11-20 2016-05-26 国立研究開発法人医薬基盤・健康・栄養研究所 異なる核酸アジュバントの組み合わせによる、新規Ｔｈ１誘導性アジュバントおよびその用途
CA3069733A1 (en) 2017-07-20 2019-01-24 Spogen Biotech Inc. Bioactive polypeptides for improvements in plant protection, growth and productivity
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2019094528A1 (en) * 2017-11-09 2019-05-16 The Scripps Research Institute An improved heroin vaccine
JP7037930B2 (ja) * 2017-12-19 2022-03-17 株式会社小糸製作所 車両の運転支援装置、命令表示装置及び車両用灯具。
CN109879940A (zh) * 2017-12-25 2019-06-14 苏州和锐生物科技有限公司 鞭毛g多肽、抗体捕获器件及试剂盒
AU2019261592A1 (en) * 2018-04-24 2020-11-19 Genome Protection, Inc. Methods for improving frailty and aging
WO2020110154A1 (en) * 2018-11-30 2020-06-04 Bharat Biotech International Limited A chimeric therapeutic vaccine
CA3122067A1 (en) * 2018-12-07 2020-06-11 Genome Protection, Inc. Engineered flagellin-derived compositions and uses
CN111718417B (zh) * 2019-03-19 2022-10-14 宁波鲲鹏生物科技有限公司 含有荧光蛋白片段的融合蛋白及其用途
KR102169663B1 (ko) * 2019-03-28 2020-10-26 가톨릭대학교 산학협력단 플라젤린으로부터 유도된 tlr5 작용제를 유효성분으로 포함하는 이식편대숙주질환의 예방 또는 치료용 조성물
US12377112B2 (en) 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
CN110157655B (zh) * 2019-05-22 2021-06-01 中国兽医药品监察所 一种无毒性气肿疽梭菌基因工程亚单位疫苗用菌种及其应用
US20220288198A1 (en) * 2019-08-30 2022-09-15 Genome Protection, Inc. Methods of increasing vaccine efficacy
JP7766623B2 (ja) 2020-05-19 2025-11-10 サイビン アイアールエル リミテッド 重水素化トリプタミン誘導体および使用方法
US20220389065A1 (en) * 2020-06-04 2022-12-08 The Catholic University Of Korea Industry-Academic Cooperation Foundation Anticancer composition comprising tlr5 agonist derived from flagellin as active ingredient
TWI746188B (zh) * 2020-09-28 2021-11-11 中山醫學大學 篩選治療腦炎藥物之平台及其方法
CA3208643A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
CN118871092A (zh) * 2021-06-30 2024-10-29 Inserm(法国国家健康医学研究院) 用于肺部递送鞭毛蛋白的气雾剂组合物
KR102483177B1 (ko) * 2021-07-09 2022-12-29 전남대학교산학협력단 탈-면역 플라젤린 및 이를 포함하는 백신 조성물
KR102514849B1 (ko) * 2021-10-28 2023-03-28 전남대학교산학협력단 수지상 세포를 표적하는 신규한 펩타이드, 및 이를 포함하는 암 치료용 조성물
AU2023281711A1 (en) * 2022-06-01 2024-11-28 Flag Bio, Inc. Rna adjuvants, methods and uses thereof
WO2024035137A1 (ko) * 2022-08-10 2024-02-15 주식회사 메디스팬 바실러스 서브틸리스 플라젤린 변이체 및 이의 용도
WO2025172452A1 (en) * 2024-02-14 2025-08-21 Institut National de la Santé et de la Recherche Médicale Combination for treating bacterial infection due to pseudomonas aeruginosa antibiotic-resistant strain

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3007812A (en) 1957-02-11 1961-11-07 Allied Chem Water-repellent compositions, method of water-proofing porous surfaces therewith, and resulting water-repellent surfaces
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5399494A (en) 1983-03-04 1995-03-21 The University Of Maryland System Vibrio cholerae strain CVD103Hgr, method of making same, and vaccines derived therefrom
US6130082A (en) 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
WO1990006696A2 (en) * 1988-12-19 1990-06-28 Praxis Biologics, Inc. Meningococcal class 1 outer-membrane protein vaccine
JPH05502402A (ja) 1990-09-28 1993-04-28 ゲブリユーダー　ズルツアー　アクチエンゲゼルシヤフト 医療用の中空針及びその製造方法
AU3630093A (en) 1992-03-02 1993-10-05 Biocine S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
US5693476A (en) 1995-02-24 1997-12-02 The Board Of Trustees Of The Leland Stanford Junior University Methods of screening for compounds capable of modulating vesicular release
US20020009747A1 (en) 1997-08-25 2002-01-24 Freda Diane Miller Methods and reagents for identifying modulators of neuronal apoptosis
US5994409A (en) 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
WO2001040280A2 (en) 1999-11-29 2001-06-07 Inotek Corporation Composition and method for treating a microbial infection
ATE360643T1 (de) 2000-01-31 2007-05-15 Munin Corp Humanes cyr61
US7300749B2 (en) 2000-02-17 2007-11-27 Millennium Pharmaceuticals, Inc. Molecules of the pyrin domain protein family and uses thereof
WO2002044363A1 (en) 2000-11-28 2002-06-06 Genesis Research And Development Corporation Limited Methods for modulating apoptotic cell death
US8703146B2 (en) 2001-04-20 2014-04-22 Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
EP1379552B2 (en) 2001-04-20 2014-11-19 The Institute for Systems Biology Toll-like receptor 5 ligands and methods of use
WO2003028659A2 (en) 2001-10-02 2003-04-10 University Of Chicago Methods and compositions for modulating apoptosis
US7078165B2 (en) 2003-03-27 2006-07-18 Institut Pasteur Method for modulating Nod1 activity, use of a MTP related molecule for modulating Nod1 activity, and therapeutic applications thereof
US7638485B2 (en) 2003-12-02 2009-12-29 Cleveland Biolabs, Inc. Modulating apoptosis
WO2005056041A2 (en) 2003-12-02 2005-06-23 Cleveland Clinic Foundation METHODS OF INHIBITING APOPTOSIS USING LATENT TGFβ
WO2005056054A2 (en) 2003-12-02 2005-06-23 Cleveland Clinic Foundation METHODS OF INHIBITING APOPTOSIS USING INDUCERS OF NF-κB
PT1706133E (pt) * 2003-12-02 2010-12-07 Cleveland Clinic Foundation Métodos para protecção contra radiação utilizando flagelina
US20050266391A1 (en) 2004-01-15 2005-12-01 Bennett Brydon L Methods for preserving tissue
US7404963B2 (en) 2004-10-01 2008-07-29 The University Of South Florida Flagellin-based adjuvants and vaccines
US7794731B2 (en) 2004-12-16 2010-09-14 Wake Forest University Health Sciences Use of flagellin in the immunotherapy of Yersinia pestis
WO2006069198A1 (en) 2004-12-22 2006-06-29 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof
EP1940419A2 (en) 2005-09-09 2008-07-09 Oregon Health and Science University Neuroprotectants
WO2007070623A2 (en) 2005-12-14 2007-06-21 Medistem Laboratories, Inc. Transcatheter tumor immunoembolization
EP1979488A4 (en) 2006-01-09 2009-05-27 Univ California IMMUNOSTIMULATING COMBINATIONS OF TNFRSF, TLR, NLR, RHR, PURINERIC RECEPTOR, AND CYTOKIN RECEPTOR ANTONISTS FOR VACCINES AND TUMOR IMMUNOTHERAPY
WO2008094275A1 (en) 2007-01-30 2008-08-07 New York University Peptides for treatment of conditions associated with nitric oxide
CN101778861A (zh) 2007-06-15 2010-07-14 Immurx公司 Tlr激动剂和/或1型干扰素减轻tnf-r激动剂治疗方案的毒性的用途
WO2009018500A1 (en) 2007-07-31 2009-02-05 The Johns Hopkins University Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
EP2224954B1 (en) 2007-11-07 2014-01-08 Celldex Therapeutics, Inc. Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
WO2009102818A1 (en) 2008-02-11 2009-08-20 Cleveland Biolabs, Inc. Method for reducing the effects of chemotheraphy using flagellin related polypeptides
PT2320948E (pt) 2008-08-01 2013-06-17 Cleveland Clinic Foundation Métodos para o tratamento de lesões por reperfusão
WO2010040096A2 (en) 2008-10-03 2010-04-08 Emory University Methods for the treatment of graft-versus-host disease
JP5913093B2 (ja) 2009-05-21 2016-04-27 アストラゼネカ アクチボラグ 新規ピリミジン誘導体と、癌とさらなる疾患の治療におけるそれらの使用
SG178954A1 (en) 2009-09-02 2012-04-27 Novartis Ag Immunogenic compositions including tlr activity modulators
AP2012006253A0 (en) 2009-10-06 2012-06-30 Panacela Labs Inc Use of toll-like receptors and agonist for treating cancer.
US9682133B2 (en) * 2010-03-17 2017-06-20 Cornell University Disrupted adenovirus-based vaccine against drugs of abuse
CN103945863A (zh) * 2011-08-01 2014-07-23 爱默蕾大学 包含配体的vlp及其相关方法
CN102965386A (zh) * 2011-09-02 2013-03-13 中国人民解放军军事医学科学院放射与辐射医学研究所 一种重组细菌鞭毛蛋白衍生多肽的制备和活性鉴定方法
CN102772795B (zh) * 2012-08-06 2015-07-29 中国人民解放军疾病预防控制所 布鲁氏菌鞭毛蛋白bmeii1112在制备布鲁氏菌亚单位疫苗中的应用
JP6940916B2 (ja) * 2014-07-30 2021-09-29 ゲノム プロテクション，インコーポレイテッド フラジェリン組成物および使用

Similar Documents

Publication Publication Date Title
JP2017523184A5 (enExample)
CL2020001897A1 (es) Tratamientos contra el cáncer de útero. (divisional solicitud 201802508)
EA202191027A3 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей
PE20240645A1 (es) Peptido inmunogenico derivado de moleculas de antigenos leucocitarios humanos (hla) como biomarcador en la inmunoterapia de diversos tumores
MX2021002543A (es) Proceso para la preparacion de composiciones de vacunas.
EP3211001A3 (en) Superagonists and antagonists of interleukin-2
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2023002554A (es) Anticuerpos anti-il-1r3 humanizados.
MX2023014457A (es) Peptidos antigenicos para la prevencion y el tratamiento del cancer.
JP2019500026A5 (enExample)
RU2016107873A (ru) Пептиды
JP2009520758A5 (enExample)
JP2018509423A5 (enExample)
FI3737397T3 (fi) Prameen kohdistetut syöpärokotteet ja niiden käytöt
CA2755897A1 (en) Treatment of cancers with immunostimulatory hiv tat derivative polypeptides
US8575319B2 (en) Cleavable vaccine compositions and uses thereof and methods of making and using the same
WO2022155403A1 (en) Recombinant polypeptides, conjugates comprising the same, and uses thereof
MX343848B (es) Vacuna de her2 dna como tratamiento adjunto para canceres en animales de compañía.
MX2022002293A (es) Péptidos recombinantes inmunotolerantes similares a la elastina y métodos de uso.
CN103254313B (zh) 组合的ctl抗原表位及其应用
EA202190186A1 (ru) Пептиды, комбинации пептидов и медикаменты на клеточной основе для применения в иммунотерапии рака мочевого пузыря и других видов рака
NZ772593B2 (en) Single-chain chimeric polypeptides and uses thereof